| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Dyadic International, Inc.$0.81
+0.02 (+2.69%)
Market Cap
32.46 M
EPS
-0.23
P/E Ratio
-3.91 $
Value Trade
100.59 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.11 M
R&D Expenses
476.07 K
Operating CF
-1.96 M
Total Assets
7.81 M
Total Liabilities
8.22 M
Equity
-407.73 K
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
5.61 M
Monthly Burn
654.00 K
Runway
7.4 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
79.50 K
52 Week Range
0.65 - 1.35
% held by Insiders
25.67 %
% held by Institutions
14.11 %
Enterprise Value
28.97 M
Total Shares
36.45 M
Short %
2.31 %
Float Shares
26.98 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DYAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Dyadic International, Inc. (DYAI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
DYAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DYAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DYAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DYAI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
DYAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DYAI
Jun 15, 2026Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption Company's C1 platform may help address urgent need for rapid, scalable vaccine and
Dyadic International, Inc. highlighted the increasing interest in its C1 biomanufacturing platform, especially in response to the Bundibugyo Ebola virus outbreak. The platform aims to expedite the manufacturing of vaccines and monoclonal antibodies, which are crucial during health emergencies. Recent collaborations with organizations like Scripps Research aim to advance the development of vaccine antigens for various infectious diseases. Dyadic's C1 platform is also viewed as a versatile solution that can support multiple industries, including food and industrial markets, indicating its commercial potential.
Read more →-DYAI
May 28, 2026Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic International is collaborating with Scripps Research to develop monoclonal antibodies and vaccines targeting hantaviruses, particularly the Andes virus. This partnership aims to enhance pandemic preparedness by utilizing Dyadic's C1 platform for rapid and scalable biologic production. The collaboration builds on previous work and seeks to address challenges in manufacturing during public health emergencies.
Read more →-DYAI
May 19, 2026Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions will present at the Sidoti Virtual Investor Conference on May 20-21, 2026. Joe Hazelton, the company's President and COO, will lead the presentation, which can be accessed live. Additionally, Dyadic will offer virtual one-on-one meetings for investors, emphasizing their commitment to engagement and transparency.
Read more →-DYAI
May 13, 2026DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial l
Dyadic International, Inc. reported its financial results for Q1 2026, highlighting substantial revenue growth of 182.3% from the previous year. The company received initial orders for recombinant bovine transferrin from the cultivated meat sector and launched AlbuFree DX recombinant human albumin. Additionally, Dyadic expanded its collaborations with Fermbox Bio and entered agreements to distribute its recombinant products globally. Despite these advancements, the company noted a decrease in cash reserves compared to the previous quarter.
Read more →-DYAI
Mar 25, 2026DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic e
Dyadic International, Inc. has reported its 2025 financial results and highlighted significant achievements in its commercial and collaborative efforts. The successful launch of AlbuFree DX and expanded partnerships with Fermbox Bio, IBT Bioservices, and BRIG Bio mark key advances in Dyadic's strategy to enhance its market presence. However, the company experienced a revenue decline and a decrease in cash position, which could pose challenges moving forward. Dyadic aims to continue its focus on developing animal-free proteins and enzymes across various sectors.
Read more →-DYAI
Mar 4, 2026Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic Applied BioSolutions and Fermbox Bio have launched their first product, animal-origin-free Recombinant DNase I, under an expanded collaboration. This enzyme is designed for nucleic-acid clean-up and supports applications in biopharmaceutical manufacturing. The companies plan to introduce additional recombinant proteins throughout 2026, targeting high-demand segments in biotechnology and molecular diagnostics.
Read more →-DYAI
Mar 2, 2026Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS announced the planned commercialization of a non-animal dairy enzyme, recombinant bovine chymosin, in 2026. This follows the successful completion of development activities under their collaboration agreement. Dyadic received a $200,000 milestone payment and is positioned to earn royalties on future sales. The partnership aims to meet the growing demand for sustainable dairy processing solutions.
Read more →-DYAI
Feb 17, 2026Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product. This launch highlights Dyadic's commitment to producing animal-free proteins for life sciences. The partnership allows Dyadic to benefit from Proliant's established distribution network. The product is aimed at meeting the growing demand for scalable and supply-secure inputs in cell culture applications.
Read more →-DYAI
Nov 12, 2025Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned websit
Dyadic International, now rebranded as Dyadic Applied BioSolutions, reported positive financial results for Q3 2025, highlighting a successful transition to a commercially-focused biotechnology provider. The company has advanced various recombinant protein programs towards market readiness and received its first purchase order for cell culture media products. Additionally, Dyadic secured a CRISPR license from ERS Genomics, enhancing its genetic engineering capabilities. With a cash position of $10.4 million, Dyadic is positioned for sustainable growth and aims to tap into rising demand in biopharma markets, particularly in Asia.
Read more →-DYAI
Oct 6, 2025Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Dyadic Applied BioSolutions has announced significant milestone achievements including a $500,000 payment from Proliant Health. The company is transitioning towards commercial focus, showcasing advancements in its collaborations with Proliant Health and Inzymes. Key developments include successful production of recombinant proteins for various markets, with future revenue growth anticipated as commercialization proceeds. However, the company faces uncertainties such as reliance on third-party partnerships and a history of net losses.
Read more →-DYAI
Aug 13, 2025Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress Completed Strategic Leadership and Operational Transformation from R&D to Commercial Operations Rebranded as Dyadic Applied B
Dyadic International, Inc. reported its financial results for the second quarter of 2025, highlighting significant progress in its transformation to a commercially oriented biotech company. The company successfully completed a $5.3 million equity offering to bolster its liquidity and fund ongoing pipeline growth. Dyadic's rebranding effort reflects a shift towards commercial execution, with several recombinant protein programs nearing commercialization. Despite increases in R&D expenses, the company achieved key milestones and recorded substantial revenue growth compared to the previous year.
Read more →-DYAI
Jul 30, 2025Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
Dyadic International, Inc. has announced a proposed public offering of common stock as of July 30, 2025. The company aims to utilize the proceeds for working capital and general corporate activities, including product development and sales. The offering is underwritten by Capital Group LLC, but its completion is subject to market conditions and other uncertainties. Additionally, the size and terms of the offering remain undefined, indicating potential risks for investors.
Read more →-DYAI
Oct 12, 2020Document Dyadic Updates Market on COVID-19 Initiatives C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Differe
Dyadic Updates Market on COVID-19 Initiatives C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators Record Expression Level of C1 SARS-CoV-2 RBD Anti
Read more →-DYAI
Mar 18, 2020Document Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress JUPITER
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress JUPITER, FLORIDA ACCESSWIRE March 18, 2020 - Dyadic International, Inc. ("Dyadic" or the Company ) (NASDAQ DYAI), a global biotechnology company
Read more →-DYAI
Feb 25, 2020Document Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Nes - Ziona, ISRAEL and JUPITER
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Nes - Ziona, ISRAEL and JUPITER, FL ACCESSWIRE February 25, 2020 Dyadic International, Inc. (''Dyadic'') (NASDAQ DYAI), a global biotechnology company announced today
Read more →-DYAI
Feb 21, 2020Document DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED - Further Extends Company's Biologic Market Opportunities - JUPITER
DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED -Further Extends Company's Biologic Market Opportunities - JUPITER, FL ACCESSWIRE February 21, 2020 Dyadic International, Inc. ("Dyadic") (NASDAQ DYAI), a global biotechnology company focused on further impr
Read more →-DYAI
Jan 27, 2020Document Dyadic to Interview with FOX Business Network on Monday
Dyadic to Interview with FOX Business Network on Monday, January 27, 2020 JUPITER, FLORIDA ACCESSWIRE January 27, 2020 - Dyadic International, Inc. ("Dyadic" or the Company ) (NASDAQ DYAI), a global biotechnology company focused on further improving and applying its proprietary
Read more →-DYAI
Jan 6, 2020Document Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019 Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top
Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019 Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Le
Read more →-DYAI
Nov 25, 2019Document DYADIC ANNOUNCES ACHIEVING HUMAN LIKE GLYCAN STRUCTURES FROM ITS ENGINEERED C1 CELL LINE - High G0 Glycosylation Level Driving Program Acceleration - JUPITER
DYADIC ANNOUNCES ACHIEVING HUMAN LIKE GLYCAN STRUCTURES FROM ITS ENGINEERED C1 CELL LINE - High G0 Glycosylation Level Driving Program Acceleration - JUPITER, FL ACCESSWIRE November 25, 2019 Dyadic International, Inc. ("Dyadic") (NASDAQ DYAI), a global biotechnology company fo
Read more →-DYAI
Feb 13, 2019Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ Jupiter, FL / ACCESSWIRE /
Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ Jupiter, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declare
Read more →-DYAI
Nov 17, 2008Codexis, Dyadic In Enzyme Production System License Agreement Redwood City, CA and Jupiter, FL
Codexis, Dyadic In Enzyme Production System License Agreement Redwood City, CA and Jupiter, FL Codexis, Inc. and Dyadic International (USA), Inc. today announced a license agreement covering use of Dyadic's C1 expression system for large-scale production of enzymes in certain f
Read more →-DYAI
Jun 19, 2008Harry Z. Rosengart Notifies Dyadic International, Inc. of His Resignation
Z. Rosengart Notifies Dyadic International, Inc. of His Resignation Fla. - June 19, 2008 - Dyadic International, Inc. (the "Company") announced today that, on June 13, 2008, Harry Z. Rosengart notified the Company of his resignation (i) as the Chairman of the Board of Director
Read more →-DYAI
Jun 5, 2008Dyadic's Executive Officers and Key Employees Announce Their Resignation
Executive Officers and Key Employees Announce Their Resignation Fla. - June 5, 2008 - Dyadic International, Inc. (the "Company") announced today that, on May 30, 2008, the Company received notice from all of its executive officers and certain key employees of their resignation
Read more →-DYAI
May 13, 2008DYADIC INTERNATIONAL, INC. 140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 NOTICE OF ANNUAL MEETING OF STOCKHOLD ERS TO BE HELD ON FRIDAY, JUNE 20, 2008, AT 10:00 A.M. To the stockholders of Dyadic Internation
Intracoastal Pointe Drive, Suite 404 ANNUAL MEETING OF STOCKHOLDERS BE HELD ON FRIDAY, JUNE 20, 2008, AT 10:00 A.M. stockholders of Dyadic International, Inc.: meeting of stockholders of Dyadic International, Inc., a Delaware corporation, will be held on Friday, June 20, 200
Read more →-DYAI
Apr 15, 2008GRANTED EFiled: Apr 15 2008 9:57AM EDT Transaction ID 19406728 Case No. 3353-VCP IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MARK A. EMALFARB, Plaintiff, v. DYADIC INTERNATIONAL, INC., Defendant. ) ) ) ) ) ) ) ) )
THE COURT OF CHANCERY OF THE STATE OF DELAWARE plaintiff Mark A. Emalfarb ("Plaintiff") brought this action pursuant to 8 Del. C. 211 to compel defendant Dyadic International, Inc. ("Defendant," or the "Company") to hold an annual meeting of the Company's stockholders for the
Read more →-DYAI
Mar 14, 2008Dyadic International, Inc. Announces Changes to its Board of Directors
International, Inc. Announces Changes to its Board of Directors Fla - March 14, 2008 - Dyadic International, Inc. (the "Company") today announced the election of Mr. Wendell H. Adair, Jr., to the Board of Directors (the "Board") of the Company. Mr. Adair replaces Mr. Richard J
Read more →-DYAI
Mar 4, 2008REPORT OF INTERNAL INVESTIGATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DYADIC INTERNATIONAL, INC. Submitted by: Moscowitz & Moscowitz, P.A. 1111 Brickell Avenue, Suite 2050 Miami, FL 33131 Phone: (305) 379-
INTERNAL INVESTIGATION Brickell Avenue, Suite 2050 Page I. Independence and Scope of the Investigation 3 II. Background Information 3 III. The Course of the Investigation 9 A. Interviews 9 B. Dyadic document reviews 11 C. Auditor document reviews 11 D. Computer forensics 11 IV
Read more →-DYAI
Jan 18, 2008Dyadic Affirms Ownership of All Intellectual Property Underlying its Technologies and Provides Other Updates
Affirms Ownership of All Intellectual Property Underlying its Technologies Provides Other Updates Fla - January 18, 2008 - Dyadic International, Inc. (the "Company") announced today that as previously disclosed in the Company's Current Reports on (filed on December 3, 2007 an
Read more →-DYAI
Jan 2, 2008LEVIN GINSBURG 80 North LaSalle Street w Suite 3200 Attorneys at Law Chicago, Illinois 60601-2800 312.368.0100
Overnight Courier, Email and Telefax No. 561-743-8343 International (USA), Inc. known as Dyadic International, Inc. Intracoastal Pointe Drive, Suite 404 Wayne Moor, Chief Executive Officer, President and Board Member Default under Revolving Note ($3,000,000.00) may recall,
Read more →-DYAI
Dec 28, 2007IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY MARK A. EMALFARB, Plaintiff, v. DYADIC INTERNATIONAL, INC., Defendant . ) ) ) ) ) ) ) ) ) ) Civil Action No. ______________ VERIFIED COMPLAIN
COURT OF CHANCERY OF THE STATE OF DELAWARE FOR NEW CASTLE COUNTY ("Emalfarb"), by and through his undersigned counsel, brings this action pursuant to 8 Del.C. setting a date for an annual meeting of stockholders of Dyadic International, Inc. ("Dyadic" or the "Company"), and
Read more →-DYAI
Dec 3, 2007Dyadic Receives Delisting Notice from American Stock Exchange and Provides Updates Regarding Gordian Strategic Process and Other Events Company Appeals Amex Decision
Receives Delisting Notice from American Stock Exchange and Provides Updates Regarding Gordian Strategic Process and Other Events Appeals Amex Decision Fla - December 3, 2007 - Dyadic International, Inc. (AMEX: DIL) announced that it has received notice from the Listing Qualif
Read more →-DYAI
Nov 19, 2007Dyadic Provides Strategic and Business Update
Provides Strategic and Business Update Fla - November 19, 2007 - Dyadic International, Inc. (AMEX: DIL) announced that it has made progress in the Gordian Group-assisted value maximization process and has taken steps to ensure that the Company is not disrupted during previous
Read more →-DYAI
Oct 3, 2007LEVIN GINSBURG 180 North LaSalle Street, Suite 3200 Attorneys at Law Chicago, Illinois 60601-2800 312.368.0100
LaSalle Street, Suite 3200 Overnight Courier and Regular Mail International (USA), Inc. known as Dyadic International, Inc. Intracoastal Pointe Drive, Suite 404 Wayne Moor, Chief Executive Officer under Revolving Note ($3,000,000.00) advised that we are counsel to the Mark
Read more →-DYAI
Oct 1, 2007Dyadic Announces Senior Management Changes and Other Events
Announces Senior Management Changes and Other Events Fla - October 1, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that on September 27, 2007, Dr. Glenn E. Nedwin resigned from all positions Dyadic International, Inc. (the "Company"), including his positions a
Read more →-DYAI
Sep 24, 2007Dyadic Announces Termination of Employment of its President and CEO, Mark A. Emalfarb
Announces Termination of Employment of its President and CEO, Mark A. Fla - September 24, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that on September 20, 2007, a special committee (the "Special Committee") of the board of directors (the "Board") of Dyadic I
Read more →-DYAI
Aug 28, 2007Dyadic's Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing Standards
Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing Fla - August 28, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that it has received a second notice from The American Stock Exchange (the "Amex") indicating that the Company continu
Read more →-DYAI
Jul 9, 2007Dyadic's Amex Listing Will Be Continued Pursuant To An Extension
Amex Listing Will Be Continued Pursuant To An Extension Fla - July 9, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today it has received notice from The American Stock Exchange (the "Amex") that Amex listing is being continued pursuant to an extension. 21, 2007, th
Read more →-DYAI
May 21, 2007Dyadic Updates Progress of Its Investigation Company announces its intent to abandon its Hong Kong and Mainland China operations Company reports receipt of delinquency notice from the American Stock Exchange
Updates Progress of Its Investigation announces its intent to abandon its Hong Kong and Mainland China reports receipt of delinquency notice from the American Stock Fla - May 21, 2007 - Dyadic International, Inc. (AMEX: DIL) today provided update on the progress of its invest
Read more →-DYAI
Apr 24, 2007Dyadic Announces Discovery of Potentially Material Operational and Financial Improprieties at its Hong Kong and Mainland China Operations
Announces Discovery of Potentially Operational and Financial Improprieties at its Hong Kong and Mainland China Fla. - April 24, 2007 - Dyadic International, Inc. (AMEX: DIL) today announced that it has discovered potentially material operational and financial improprieties at
Read more →-DYAI
Nov 20, 2006DYADIC ANNOUNCES $13 MILLION PRIVATE PLACEMENT Jupiter, Florida
ANNOUNCES $13 MILLION PRIVATE PLACEMENT Florida, November 20, 2006 - Dyadic International, Inc. (AMEX: biotechnology company, announced today that on November 17, 2006, it entered into a definitive agreement with institutional investors to purchase in a private placement 2,78
Read more →-DYAI
Oct 27, 2006Abengoa Press Release DYADIC ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH ABENGOA BIOENERGY IN THE AREA OF CELLULOSIC ETHANOL PRODUCTION ABENGOA BIOENERGY TO PURCHASE $10 MILLION OF DYADIC COMMON STOCK Jupiter, Fl
ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH ABENGOA BIOENERGY IN THE AREA OF CELLULOSIC ETHANOL PRODUCTION BIOENERGY TO PURCHASE $10 MILLION OF DYADIC COMMON STOCK Florida, October 27, 2006. Dyadic International, Inc. (AMEX: biotechnology company, today announced that
Read more →-DYAI
May 4, 2006Dyadic Press Release Dated 5/04/06 Dyadic Increases Ownership in its Asian Subsidiary to 100%
Increases Ownership in its Asian Subsidiary to 100% Fla. - May 4, 2006 - Dyadic International, Inc. (AMEX: DIL), a global biotechnology company (the "Company"), with subsidiaries in Hong Kong and mainland China, Poland, and The Netherlands, announced today that on April 2006,
Read more →-DYAI
May 2, 2006Press Release dated
Receives $2.1 Million in Cash from Exercise of Warrants and Stock Options and Announces $1.6 Million Debt-for-Equity Conversion by its Two Largest Stockholders, including the Company's Fla. - May 3, 2006 - Dyadic International, Inc. (AMEX: DIL), a biotechnology company, annou
Read more →-DYAI
Mar 21, 2006Glenn Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic International as Chief Scientific Officer and President of its Biosciences Business
Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic International as Chief Scientific Officer and President of its Biosciences Fla. - March 21, 2006 - (via Business Wire) - Dyadic International, Inc. (AMEX: DIL), biotechnology company, announced to
Read more →-DYAI
Dec 21, 2005TERMINATION AND LICENSE AGREEMENT THIS TERMINATION AND LICENSE AGREEMENT (this " Agreement ") is made as of the 19th day of December and effective as of
AND LICENSE AGREEMENT TERMINATION AND LICENSE AGREEMENT (this "Agreement") is December and effective as of November 23, 2005 (the "Effective corporation ("Dyadic International (USA), Inc., Florida, USA corporation ("Dyadic International, Inc., Delaware, USA corporation ("D
Read more →-DYAI
Apr 28, 2005v017127_ex99-1.txt DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 26th day of April, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corpor
DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 26th day of April, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and Harry Rosengart ("Indemnitee"). A. The Company
Read more →-DYAI
Apr 15, 2005v016572_ex99-1.txt [logo] Dyadic International, Inc. Dyadic International, Inc. 140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 (561) 743-8333 http://www.dyadic-group.com --------------------------------------
[logo] Dyadic International, Inc. Dyadic International, Inc. 140 Intracoastal Pointe Drive, Suite 404 http://www.dyadic-group.com -------------------------------------------------------------------------------- DYADIC REPORTS YEAR-END 2004 FINANCIAL RESULTS Jupiter, Florida
Read more →-DYAI
Apr 1, 20051.txt DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 29th day of March, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "C
DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 29th day of March, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and Robert Shapiro ("Indemnitee"). A. The Company a
Read more →-DYAI
Feb 1, 20051.txt EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 31st day of January, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the
EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 31st day of January, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and WAYNE MOOR (the "Executive"). The Company and
Read more →-DYAI
Jan 10, 2005v011187_ex99-1.txt DYADIC INTERNATIONAL, INC. STATEMENT OF DIRECTOR COMPENSATION POLICY THIS STATEMENT OF DIRECTOR COMPENSATION POLICY (the "Director Compensation Policy") sets forth the policies of Dyadic International,
DYADIC INTERNATIONAL, INC. DIRECTOR COMPENSATION POLICY THIS STATEMENT OF DIRECTOR COMPENSATION POLICY (the "Director Compensation Policy") sets forth the policies of Dyadic International, Inc, a Delaware corporation (the "Company") pertaining to the remuneration which the C
Read more →Competitive Position
How DYAI ranks across every disease it competes inCompetitive Position is a premium feature
See how DYAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial